



Date: April 10, 2025

To: FHCP Network Providers

From: Florida Health Care Plans Quality Management Department

Re: HEDIS Quality Measures IET of Substance Use Disorder Treatment

Please see the attached information regarding HEDIS Quality Measures IET of Substance Use Disorder Treatment.

If there are any questions or concerns regarding this important announcement, please contact Kristina Wald at kmazon@fhcp.com or 386.676.7100 Extension 7698



**Florida
Health Care
Plans®**



An Independent Licensee of the Blue Cross and Blue Shield Association

Date: April 7, 2025

To: Primary Care, Urgent Care, and ER Physicians, APRNs, and PAs, Specialists to include Pain Management, Cardiology, Gastroenterology, Gerontology, Neurology, Pulmonology, Gynecology, Behavioral Health Providers (Psychiatrists, APRNs, PAs, LMHCs, LMFTs, LCSWs, and Doctor on Demand)

From: FHCP Quality Management Department

**Re: HEDIS® Quality Measure IET
Initiation and Engagement of Substance Use Disorder Treatment**

Early and regular SUD treatment, including medication therapy, has been demonstrated to improve overall health outcomes for individuals with SUDs.

Initiation and Engagement of Substance Use Disorder Treatment (IET) is one of the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®) measures.

The HEDIS® IET quality measure indicates that adults and adolescents 13 years of age and older with a new substance use disorder (SUD) episode should have the following:

- Initiation: Treatment initiation within **14 days** of the episode. This can include inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth, or medication treatment event.
- Engagement: **Two** additional SUD services within **34 days** of treatment initiation. This can include an engagement visit or medication treatment event (any combination).

Helpful HEDIS® Practice Tips:

- Alcohol, opioid, and other substance use disorders, including abuse and dependence, indicate there is a need for treatment and follow-up care.
- Please consider using alternative Z codes for substance use when clinically appropriate.
- Submitted claims must include the visit code, original episode diagnosis, and, when applicable, a place of service code.
- Please consider medications for alcohol and opioid use disorders when clinically appropriate as they qualify for a medication treatment event.

Please see attachment for additional information. If you have any questions, please contact: Kristina Wald, Behavioral Health Administrator, (386) 676-7100, Ext. 7698, or email kmazon@fhcp.com.



**Florida
Health Care
Plans®**



An Independent Licensee of the Blue Cross and Blue Shield Association

Codes Which Do NOT Trigger Measure:

Description	Code
Alcohol Use, Caffeine Use	Z 72.89
Long Term (Current) Use of Opiate Analgesic	Z 79.891
Long Term (Current) Use of Benzodiazepine; Long Term (Current) Use of Stimulant for ADHD; Medical Marijuana Use	Z 79.899

IET HEDIS® Measure Coding Tips:

An SUD diagnosis must be included in the claim along with one of the following:

Outpatient Visit

CPT	+	POS
90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255		Intensive Outpatient Encounter or Partial Hospitalization POS: 52 Community Mental Health Center POS: 53 Telehealth POS: 02, 10 Outpatient POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72 Non-residential substance abuse treatment facility POS: 57, 58

BH/Outpatient Visit

CPT
98960-98962, 99078, 99202-99205, 99211- 99215, 99242-99245, 99341, 99342, 99344, 99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510

Substance Use Disorder Service

CPT and Code
99408, 99409, Z 71.41, Z 71.51

Telephone Visit

CPT
98966-98968, 99441-99443

E Visit or Virtual Check-In (Online)

CPT
98966-98968, 99441-99443

Medication Events

Medications	
Naltrexone (oral, injectable)	Disulfiram (oral)
Buprenorphine (SL tablet, injection, implant)	Acamprosate (oral, delayed-release tab)
Buprenorphine/naloxone (SL tablet, buccal film, SL film)	